Champignon Brands (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496), a
human optimization sciences company focused on applying novel and natural
treatment protocols to address a broad range of disorders and deficiencies with
an emphasis on psychedelic medicine, today announced the appointment of Pat
McCutcheon to the company’s board of directors, effective immediately.
McCutcheon is currently the chief executive officer of one of the leading
global cannabis companies, MediPharm Labs Corp. (TSX: LABS), and has held
senior roles with various large pharmaceutical companies. Champignon also
announced the appointment of Matthew Fish, JD as president and secretary. In
his private practice as a securities lawyer, Fish has established expansive
knowledge regarding public companies, capital markets, and mergers &
acquisitions. Fish will utilize his experience to assist SHRM in fast-tracking
its North American new clinical entity roll-out. “We are tremendously pleased
to have Pat join the Champignon Board,” Champignon CEO and director Gareth
Birdsall stated in the news release. “His extensive experience in commercial
development across the pharmaceutical industry combined with direct experience
operating and scaling highly profitable businesses further strengthens our
board with expertise that will accelerate the expansion of our clinical
footprint via the establishment of net new clinical entities, as well as
industry partnerships for ketamine, psilocybin and MDMA.”
To view the full press release, visit http://ibn.fm/dDVbm
About Champignon Brands Inc.
Champignon Brands (CSE: SHRM) is focused on the formulation
and manufacturing of novel ketamine, anaesthetics and adaptogenic delivery
platforms for the nutraceutical and psychedelic medicine while being supported
by a leading psychedelics medicines clinic platform. The Company is pursuing
the development and commercialization of rapid onset treatments capable of
improving health outcomes, such as depression and post-traumatic stress
disorder (“PTSD”), as well as substance and alcohol use disorders. Under a
collaborative research agreement with the University of Miami’s Miller School
of Medicine, the Company is conducting preclinical studies and eventual human clinical
trials, with the objective of demonstrating safety and efficacy of the
combination of psilocybin and cannabidiol in treating mTBI with PTSD or
stand-alone PTSD. Champignon continues to be inspired by sustainability, as its
medicinal mushroom-infused SKUs are organic, non-GMO and vegan certified. For
more information, visit the company’s website at www.ChampignonBrands.com.
NOTE TO INVESTORS: The latest news and updates
relating to SHRM are available in the company’s newsroom at http://ibn.fm/SHRM
About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide
a rapid summary of corporate news that catch the attention of QualityStocks.
QualityStocksBreaks are designed to keep investors up to date on important and
breaking news in the small-cap and micro-cap markets. Spanning all industries,
including energy, entertainment, telecommunications, healthcare, retail and
more, these news breaks deliver opportunities the investment community may have
missed. Whether it is earnings results, mergers and acquisitions, or any other
market-moving news, our news breaks keep you in the know. QualityStocks is
committed to connecting subscribers with companies that have huge potential to
succeed in the short and long-term future. It is part of our mission statement
to help the investment community discover emerging companies that offer
excellent growth potential.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the
QualityStocks website applicable to all content provided by QS, wherever
published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment